Abstract 177TiP
Background
In cancer, tumor-secreted factors and surgical stress responses induce the migration of myeloid-derived suppressor cells (MDSC) from the bone marrow to the circulation and tumor microenvironment (TME). Due to severe immunosuppression, this process promotes disease progression and negatively affects treatment outcomes. Limited knowledge exists regarding MDSC in colorectal cancer (CRC). Through the use of flow cytometry and a precise gating strategy, we have identified and quantified 3 classes of MDSC in CRC and confirmed their immunosuppressive capacity. Initial findings show an increase of MDSC. Future investigations will focus on comparing MDSC levels among different CRC stages and examining their spatial distribution in the TME. This research aims to enhance our understanding of how MDSC contribute to tumor cell immune evasion and impact treatment outcomes. End of study: end of 2025.
Trial Design
A cohort of 250 patients with operable CRC have pre- and postoperative blood samples drawn for analysis. Flow cytometry is performed on isolated peripheral blood mononuclear cells. Controls are healthy individuals and patients undergoing surgery for non-malignant disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Center for Surgical Science, Zealand University Hospital.
Funding
Familien Erichsen’s Mindefond (The Erichsen Family Memorial Fund).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract